Short Interest in OHR Pharmaceutical Inc (NASDAQ:OHRP) Rises By 34.4%

OHR Pharmaceutical Inc (NASDAQ:OHRP) was the target of a significant increase in short interest during the month of June. As of June 30th, there was short interest totalling 284,000 shares, an increase of 34.4% from the May 30th total of 211,300 shares. Based on an average daily volume of 109,900 shares, the short-interest ratio is currently 2.6 days. Approximately 10.6% of the shares of the company are short sold.

An institutional investor recently bought a new position in OHR Pharmaceutical stock. Mariner Investment Group LLC acquired a new stake in shares of OHR Pharmaceutical Inc (NASDAQ:OHRP) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 24,397 shares of the biotechnology company’s stock, valued at approximately $55,000. Mariner Investment Group LLC owned 0.86% of OHR Pharmaceutical at the end of the most recent quarter. Institutional investors own 10.70% of the company’s stock.

Shares of NASDAQ:OHRP traded up $1.25 during trading on Friday, hitting $5.39. 1,579,642 shares of the company were exchanged, compared to its average volume of 164,807. The firm’s 50 day moving average is $3.43. OHR Pharmaceutical has a 52-week low of $1.60 and a 52-week high of $6.28.

OHR Pharmaceutical (NASDAQ:OHRP) last posted its earnings results on Wednesday, May 15th. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter.

OHR Pharmaceutical Company Profile

OHR Pharmaceutical, Inc operates as a development stage pharmaceutical company. The company intends to merge with NeuBase Therapeutics, Inc that focuses on advancing NeuBase's peptide-nucleic acid antisense oligonucleotide technology platform for the development of therapies to address severe and currently untreatable diseases caused by genetic mutations.

Further Reading: Put Option Volume

Receive News & Ratings for OHR Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OHR Pharmaceutical and related companies with's FREE daily email newsletter.